In cultured uterine leiomyoma cells, AR agonists were demonstrated to increase the expression levels of estrogen receptor (ER), progesterone receptor (PR), vascular endothelial growth factor (VEGF), and fibroblast growth factor (FGF) via cAMP-dependent signaling pathways to influence uterine myomagenesis [56]. The gene discussed is AR; the disease is uterine corpus leiomyoma.